Owing to the loss of heterochromatin integrity that occurs during thyroid tumorigenesis, the expression of Heterochromatin Protein 1 isoforms HP1a and HP1b was assessed by immunohistochemistry in 189 thyroid tumors and non-neoplastic tissues. Expression of HP1b was significantly decreased in all thyroid lesions, except in follicular adenomas, when compared with matched adjacent normal tissue. This loss of HP1b expression may in part be caused by microRNA dysregulation. An example is miR-205, a microRNA that is abundantly upregulated in thyroid carcinomas and shown to reduce the expression of HP1b. In contrast to HP1b, HP1a expression was only reduced in metastatic carcinomas and poorly differentiated lesions. These results suggest the reduction of HP1b followed by a decrease in HP1a contributes to the pathogenesis of thyroid carcinomas, and their loss is a potential marker of thyroid malignancy and metastatic potential, respectively.
During malignant transformation nuclear architecture becomes more disorganized, with observable changes occurring in heterochromatin aggregation. 1 The human genome encodes three Heterochromatin Protein 1 (HP1) isoforms (a, b, and g), which are essential chromatin packaging proteins that function to restrict chromatin plasticity. 2 HP1a and HP1b are the isoforms found in heterochromatin and are primarily associated with gene repression. Although generally ubiquitous in normal tissue, differential expression of each HP1 isoform has been observed in both human tumor derived tissues and cells. [3] [4] [5] [6] [7] [8] [9] The pattern of expression for HP1 isoforms in solid tumors appears to vary with the tumor context. 3, 5, 7, 9, 10 Loss of HP1b expression has been reported in poorly differentiated colon cancers, invasive melanoma lesions, and prostate cancer. [11] [12] [13] Loss of HP1a expression has been observed in metastatic lesions, 5 and in medulloblastomas and advanced papillary thyroid carcinomas with poor outcome. 7, 9 However, increased HP1a has also been observed in a variety of solid tumors compared with nontumor tissue. 3 Thyroid neoplastic lesions range from benign follicular adenomas to malignant but relatively indolent papillary or follicular carcinomas, and to the highly aggressive poorly differentiated or undifferentiated anaplastic carcinomas. Both papillary and follicular well-differentiated carcinomas, comprised of differentiated follicular cells, may metastasize or give rise to the undifferentiated anaplastic carcinomas that have a poor outcome. 14, 15 Preoperatively, a common diagnostic problem is distinguishing between benign and malignant thyroid nodules, as this will influence management. Therefore, identifying specific markers that can be useful in improving the accuracy of diagnosis and predicting tumor behavior is of utmost priority.
A myriad of alterations occur at the molecular level across this spectrum of thyroid lesions causing the dysregulation of gene and microRNA (miRNA) expression. 16 It has been proposed that of the miRNAs that are dysregulated only those which are highly overexpressed or strongly downregulated are involved in thyroid tumorigenesis. 17 Thyroid cancers exhibit aberrant miRNA expression that leads to the altered expression of oncogenes as well as tumor suppressor genes. 17, 18 Interestingly, several miRNAs that are differentially upregulated in thyroid lesions are also predicted to target the HP1 family. 19 The need for improved accuracy in the diagnosis of thyroid lesions has led us to explore the expression of HP1a and HP1b across benign and malignant thyroid tumors, respectively. Screening of a thyroid tumor tissue microarray (TMA) demonstrated that HP1a expression was reduced in more advanced thyroid carcinomas, but was unchanged in well-differentiated thyroid neoplasms when compared with normal thyroid tissue. However, when compared with normal thyroid tissue, HP1b expression was significantly decreased in all thyroid neoplasms (Po0.01), except in follicular adenomas. Results indicate that a significant loss of HP1b may confer a malignant potential. We show that loss of HP1b could in part be due to the upregulation of specific miRNAs that are observed in thyroid tumors. These results suggest that the differential loss of HP1a and HP1b represents potential molecular markers for different stages of thyroid malignancy.
MATERIALS AND METHODS Tissue Microarrays
TMAs were constructed using 189 formalin-fixed paraffinembedded tissue blocks from 103 patients with benign and malignant thyroid tumors. Histological classification was based on diagnostic reports and slide re-reviews by two experienced pathologists (T Kroll and M Tretiakova). Questionable cases were not selected for inclusion. Hematoxylin and eosin-stained sections from lobectomy, partial and total thyroidectomy specimens were analyzed to define representative lesional regions and normal adjacent thyroid tissue regions. From these regions, a minimum of two duplicate tissue cylinders with a diameter of 1 mm were obtained and arrayed into recipient blocks using an automated tissue microarrayer (ATA-27, Beecher Instruments, Sun Prairie, WI, USA). The distribution of tissues was as follows: colloid nodules (N ¼ Fresh frozen, matched thyroid normal and papillary carcinoma tissue from four patients was obtained from Christchurch Cancer Society Tissue Bank, Christchurch, New Zealand. This study was approved by the New Zealand Upper South B Regional Ethics Committee and the University of Chicago Institutional Review Board.
Antibodies
The primary antibodies used for this study were the HP1a (C7F11) rabbit monoclonal antibody (Cell Signaling Technology, Danvers, MA, USA), HP1b (MAC353) rat monoclonal antibody (Abcam, Cambridge, MA, USA), and a-tubulin rat monoclonal antibody (Abcam).
Immunohistochemistry
Immunohistochemical staining was performed using HRPlabeled dextrose-based polymer complex bound to secondary antibody EnVision (Peroxidase/DAB þ ) from DAKO (Glostrup, Denmark). After deparaffinization and rehydration, slides were blocked for endogenous peroxidase with 3% H 2 O 2 for 15 min at room temperature (RT), and then washed in Tris-buffered saline (TBS). Antigen retrieval was carried out by heating sections either in Tris-EDTA buffer (pH 9.0) for 15 min in a microwave oven or in 0.1 M citrate buffer (pH 6.0) for 3 min in a pressure cooker. Non-specific binding sites were blocked using Protein Block (DAKO) for 20 min at RT in a moist chamber. Then slides were incubated, at RT for 1 h or at 4 1C in a moist chamber overnight, with the HP1a (1:200) or HP1b (1:300) antibodies diluted in Antibody Diluent (DAKO) as indicated. After TBS washes, staining was detected with EnVision system (DAKO) developed for 5 min with 3-3 0 -diaminobenzidine chromogen, counterstained with hematoxylin, and coverslipped. Negative controls were performed by substituting the primary antibody with nonimmune mouse immunoglobulins.
Evaluation of Immunostaining
Only nuclear labeling was accepted as specific for HP1. Nuclear expression was quantified manually using 200-500 cells at Â 400 magnification, as well as by using Chromavision Automated Cellular Imaging System (ACIS, Clarient Inc, Aliso Viejo, CA, USA). Manual nuclear intensity scoring was graded semiquantitatively as negative (0), weak (1 þ ), moderate (2 þ ), or intense (3 þ ) for each case. Automated ACIS scoring was applied to derive both intensity and percentage staining as previously described. 20 In brief, nuclear staining for HP1 was quantified based on three-color parameters: hue, luminosity, and saturation. Positive brown nuclear staining was recorded as a numerical score between 0 and 225 for each pixel and normalized to an area of 1 mm
In addition, the ACIS software was instructed by setting color-specific thresholds to determine brown (positive stain) from blue (negative counterstain) in the nuclei within each TMA core, and calculate the percent of nuclear positivity.
Statistical Analysis
Statistical analysis was performed using STATA (College Station, TX, USA) software package. Nuclear expression levels were calculated as the mean of duplicate measurements±s.d. P-values were calculated using a two-tailed Student's t test for continuous variables. Correlations were calculated using the Spearman rank correlation test unless otherwise indicated. Po0.05 was considered to be statistically significant. Microarray data from GEO project GSE3467 was analyzed using the websites (http://www.ncbi.nlm.nih. gov/geo/) GEO2R application with the default settings.
Cell Culture
The Nthy-ori 3-1 cell line (ECACC, Wiltshire, UK), derived from the normal thyroid follicular epithelial tissue of an adult that had been immortalized with SV40 large T antigen, was maintained in RPMI 1640 with 10% fetal bovine serum, 1% Penicillin/Streptomycin (Life Technologies, Grand Island, NY, USA) at 37 1C with 5% CO 2 in a humidified atmosphere.
Transfection with Pre-miR miRNA Precursors Nthy-ori 3-1 cells were transfected with 30 nM Pre-miR miRNA Precursors (Life Technologies) using X-tremeGENE siRNA Reagent (Roche Applied Science, Indianapolis, IN, USA) and Opti-MEM medium (Life Technologies). Media was replaced 24 h post transfection. Cells were plated at a density of 8.5 Â 10 3 cells/cm 2 to permit growth, without reaching confluency after 72 h.
HP1b 3
0 UTR Luciferase Reporter Assay pMIR-REPORT luciferase vectors (Life Technologies) haboring HP1b 3 0 UTR sequences with a wild-type (pMIR-REPORT-HP1b WT) or mutated (pMIR-REPORT-HP1b Mut) predicted miR-205 binding site were generated. Annealed oligonucleotides, spanning the region from 240 to 290 bp of the HP1b 3 0 UTR, that contained either a WT or Mut miR-205 seed region were cloned into the HindIII and SpeI restriction sites of the pMIR-REPORT vector. The sequences are shown in Figure 4a .
Nthy-ori 3-1 cells were co-transfected, as above, with the 5 nM Pre-miR miRNA Precursors (Life Technologies) and either 150 ng pMIR-REPORT-HP1b WT or Mut vector along with 100 ng pMIR-REPORT b-galactosidase control plasmid (Life Technologies). After 30 h, luciferase measurements were performed using the Luciferase Reporter Assay System (Promega, Madison, WI, USA). Firefly luciferase activity was normalized to b-galactosidase activity.
Protein Extraction
Total protein was isolated from frozen matched thyroid normal and papillary carcinoma tissue (31-82 mg) using the mirVana Paris Kit (Life Technologies). The frozen tissue was placed in cold cell disruption buffer supplemented with Complete Protease inhibitor (Roche Applied Science) and homogenized on a Retsch MM301 tissue mill at 1000 rpm for 10 min, then incubated for 10 min at 4 1C. The supernatant was collected after centrifugation at 10 000 g at 4 1C.
Total protein from the Nthy-ori 3-1 cell line was obtained by washing cells twice in PBS, incubating the cells in cold lysis buffer (50 mM HEPES pH 8.0, 400 mM NaCl, 1% NP40, Complete Protease Inhibitor) then collecting the supernatant as above. The protein concentration was determined using the BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA).
Immunoblot Analysis
Samples were resolved by SDS-PAGE and then transferred to nitrocellulose. The blots were blocked for 1 h at RT with 5% BSA in 25 mM Tris, 150 mM NaCl pH 7.6 and 0.1% Tween-20 (TBS-T), then incubated with antibodies against, either HP1a, HP1b or a-tubulin in 5% BSA/TBS-T for 18 h at 4 1C. Blots were then washed four times in TBS-T, incubated 1 h at RT with the appropriate ECL HRP-linked whole secondary antibody (GE Healthcare, Buckinghamshire, UK) diluted in 5% BSA/TBS-T and washed as before, then developed with ECLplus Western Blotting Detection (GE Healthcare).
RESULTS

HP1a Expression is Reduced in Metastatic Thyroid Neoplasms
To determine the level of HP1a protein expression in thyroid tumors, a TMA containing 189 thyroid lesions and normal adjacent thyroid tissue was screened for HP1a expression by immunohistochemistry. To ensure our results were representative of each tumor, the nuclear expression of HP1 was quantified manually by grading 2-3 cores, from 0 (negative) to 3 þ (intense), and then averaging to give the intensity of HP1 staining for each tissue. The results are graphed in Figure 1a , with representative tissue sections shown in Figure 1b . The expression of HP1a in carcinomas was comparable to that observed in normal tissue (Figure 1a) , whereas HP1a protein levels were slightly increased in adenomas compared with normal tissue and colloid nodules. A reduction of HP1a expression was observed in metastatic and anaplastic variants, however, this was not significant when compared with normal tissue. When the carcinomas were divided into non-metastatic (primary) and metastatic (either regional or distal) groups, a significant reduction (Po0.05) in HP1a expression was observed between papillary carcinomas and their metastatic counterparts (Figure 1c ).
Differential Loss of HP1b Expression in Thyroid Lesions
The thyroid TMA was also screened for HP1b protein expression and graded as described above. Normal thyroid tissue that demonstrated strong HP1b nuclear positivity served as a positive control. HP1b expression was significantly decreased (Po0.01) in all thyroid lesions, except follicular adenomas and colloid nodules, when compared with normal thyroid tissue by manual scoring for intensity of staining (Figures 2a and b) .
Automated HP1b scoring similarly showed a significant decrease in both percent of nuclear positivity and staining intensity for all lesional tissues except follicular adenoma (Po0.001, Table 1 ). Group comparison showed significant differences in staining intensity between normal/benign and malignant lesions with gradual loss of HP1b with malignant progression (Po0.001). We found a strong positive correlation between automated and semiquantitative manual grading of nuclear intensities for HP1b (r ¼ 0.62-0.75).
In general, ACIS brown staining intensity scores below 100 were equivalent to negative (0) staining by manual grading, 100-110 was equivalent to weak (1 þ ) staining, 111-120 was equivalent to (2 þ ) staining and 4120 was equivalent to (3 þ ) strong nuclear reactivity.
The specificity of the antibodies that recognize HP1b and HP1a was confirmed by immunoblot analysis using total protein extracted from three frozen advanced papillary carcinomas and a Hurthle cell variant, each showed a single band specific for the protein (Figure 2c ). This analysis also confirmed the reduction of HP1a and HP1b expression in metastatic papillary carcinomas observed by immunohistochemistry.
HP1b Expression is Altered in Thyroid Cells Overexpressing miR-205
Of the numerous miRNAs differentially upregulated in various histopathological types of thyroid tumors compared with normal tissue, miR-205 is predicted to target HP1b (TargetScanHuman, 2009). 17, 19 We observed a strong negative correlation of miR-205 and HP1b expression (Pearson r ¼ À 0.52) in previously published array data from papillary carcinomas (Figure 3a) . 21 These data show that miR-205 and HP1b were significantly up and downregulated (Po0.05), respectively in these tumors. Not surprisingly though a negative correlation with HP1b expression was also observed for other upregulated miRNAs such as miR-10a (Pearson r ¼ À 0.73) even though miR-10a is not predicted to target HP1b. 19, 22 Therefore, to determine if increased expression of miR-205 can alter the level of endogenous HP1b protein, immortalized Nthy-ori 3-1 thyroid cells were transiently transfected with a selection of Pre-miR miRNA precursors that are processed by the cell into mature miRNAs. Cells overexpressing miR-205 showed reduced HP1b protein levels compared with mock transfected cells and those transfected with a scrambled pre-miRNA precursor control (NC2) that does not have any predicted endogenous targets (Figure 3b) . Overexpression of miR-200a, another miRNA predicted to target HP1b but with reduced complementarity to its seed region in the 3 0 UTR of HP1b compared with that of miR-205, only slightly reduced the level of endogenous HP1b. Both miR-10a and miR-223, not predicted to target HP1b, did not alter the level of endogenous HP1b. As a further control, none of the tested miRNAs were predicted to target HP1a and, as shown in Figure 3b , they do not alter the level of endogenous HP1a protein in these cells. Similar results were observed when these Pre-miR miRNAs were transiently transfected into HeLa cervical carcinoma cells (data not shown).
To determine if miR-205 post-transcriptionally regulates HP1b expression directly, we used a 3 0 UTR luciferase reporter assay. The 3 0 UTR region of the CBX1 (HP1b) gene that is a predicted binding site for miR-205 was cloned into the 3 0 UTR of the pMIR-REPORT vector (Figure 4a ). Nthy-ori 3-1 cells were co-transfected with this reporter vector (WT) or one where the putative HP1b 3 0 UTR seed region has been altered to prevent binding of miR-205 (Mut), along with the pre-miRNA precursors. The transfection of pre-miRNA scrambled (NC2) and miR-10a precursors, which do not alter endogenous HP1b levels in Nthy-ori 3-1 cells (Figure 3b ), demonstrated no difference in luciferase activity between the pMIR-REPORT-HP1b WT and Mut vectors (Figure 4b ).
In the presence of miR-205, there was a 30% reduction (Po0.05) in luciferase activity in cells transfected with the pMIR-REPORT-HP1b vector containing the WT HP1b 3 0 UTR region compared with the Mut sequence that prevents binding of miR-205 (Figure 4b ). This suggests that the observed reduction in HP1b expression in thyroid tumors may in part be due to miR-205 downregulating HP1b posttranscriptionally by binding its 3 0 UTR.
DISCUSSION
The altered expression of two HP1 isoforms during thyroid tumorigenesis is not surprising given thyroid cancers generally exhibit a loss of heterochromatin integrity at the microscopic level. 1 Thyroid carcinomas demonstrate a significant reduction in the level of HP1b compared with either normal tissue, proliferative colloid nodules, or benign follicular adenomas (Figure 2 ). The decrease in HP1b expression between follicular adenoma and carcinoma groups was particularly dramatic (4.7-fold) and could have diagnostic implications. This downregulation of HP1b likely contributes to tumor progression, as knockdown of HP1b in cancer cell lines promotes chromatin disorganization, genomic instability and also increases their invasiveness. 12, 23 In contrast to the changes in HP1b expression, HP1a levels in adenomas and non-metatastic carcinomas were comparable to or increased slightly from those in normal tissue (Figure 1 ). However, HP1a expression was reduced in metastatic carcinomas from regional or distal sites. This corresponds with observations in breast tissue where noninvasive breast carcinomas were shown to have high levels of HP1a protein, 3 whereas metastatic lesions from distant sites in the body had decreased levels of HP1a. 5 This suggests that HP1a has a role in suppressing metastasis and is supported by the overexpression of HP1a decreasing the invasive potential of a breast cancer cell line. 24 Together these results show a differential loss of HP1 isoform expression during malignancy in thyroid tissue and preliminary immunohistochemical analyses suggests this pattern is common to other solid tumor types (data not shown). How the expression of each HP1 isoform is downregulated is poorly understood. In thyroid tumors, reduced expression is unlikely to be due to a decrease in the copy number of HP1b CBX1) or HP1a (CBX5) gene, as loss of 17q21.32 or 12q13.13, respectively, has not yet been observed. [25] [26] [27] MiR-205 has been shown to be significantly upregulated in papillary and anaplastic carcinomas compared with hyperplastic nodules and normal thyroid tissue. 19 As miR-205 can directly target the 3 0 UTR of HP1b (Figure 4b ), loss of HP1b in these carcinomas could be due to miR-205 posttranscriptionally downregulating HP1b expression. This demonstrates that the expression of the HP1 isoforms could be regulated post-transcriptionally. Given that the reduction of HP1b is observed across a range of malignant thyroid lesions, it will be of interest to uncover other transcriptional and post-transcriptional regulators.
In summary, these results suggest that the differential expression of HP1a and HP1b across benign and malignant tumors can be further explored as potential markers, when loss of HP1b and HP1a can be interpreted in favor of malignancy or carcinoma with metastatic potential, respectively. It will be of interest to explore the contribution of the decreased expression of these HP1 isoforms to the pathogenesis and progression of thyroid carcinomas. 
